IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

Summary

This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non-Hodgkin lymphoma (NHL).

Timeline

Start

2023-09-05

Primary completion

2026-09

Completion

2028-09

Drugs

Indications